January 15th 2021
By Tony Hagen
CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.
January 13th 2021
Charles Bennett, MD, PhD, a hematologist and oncologist and professor in the Clinical Pharmacy and Outcomes Sciences Department of the College of Pharmacy at the University of South Carolina, discussed the FDA’s pace of biosimilar approvals and the findings from his recent study.
January 12th 2021
By Deana Ferreri, PhD
Authors of a new study conclude that artificial intelligence could improve the selection of biosimilars for therapy.
January 11th 2021
Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.
January 6th 2021
Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.
January 3rd 2021
An expansion of its Reykjavik, Iceland, headquarters operation will speed the company on its way to launching its first biosimilars, officials said.
December 31st 2020
China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.
December 29th 2020
Many firsts may be in store for the biosimilar industry in 2021, although it will be dogged by ongoing difficulties, Center for Biosimilars® Advisory Board members said.
December 28th 2020
Incremental gains in the number of approved biosimilars and no new biologic categories were the low points, but uptake and improved patient access were highlights of 2020.
December 27th 2020
In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.
